Sankyo Pharma Gmbh clinical trials
Acquired by Daiichi Sankyo, Sep 28, 2005 · source ↗
The registry lists 9 studies whose lead sponsor is Sankyo Pharma Gmbh. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 24, 2018.
Before and after it joined Daiichi Sankyo
- First submitted before Sankyo Pharma Gmbh became part of Daiichi Sankyo
- 7
- First submitted after Sankyo Pharma Gmbh became part of Daiichi Sankyo
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Sankyo Pharma Gmbh9 studies
Something wrong with this grouping? Tell us on the Daiichi Sankyo page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Daiichi Sankyo studies →
- Amlodipine as add-on to Olmesartan in HypertensionCompletedNCT00220220Phase 3
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted before Sankyo Pharma Gmbh became part of Daiichi Sankyo
- Olmesartan as an add-on to Amlodipine in HypertensionCompletedNCT00220233Phase 3
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted before Sankyo Pharma Gmbh became part of Daiichi Sankyo
- Olmesartan and an add-on Treatment in Patients With Mild to Moderate HypertensionCompletedNCT00311155Phase 4
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted after Sankyo Pharma Gmbh became part of Daiichi Sankyo
- Olmesartan Medoxomil in Hypertension and Renal ImpairmentCompletedNCT00151827Phase 3
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted before Sankyo Pharma Gmbh became part of Daiichi Sankyo
- Olmesartan Medoxomil in Diabetes MellitusCompletedNCT00185159Phase 3
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted before Sankyo Pharma Gmbh became part of Daiichi Sankyo
- Olmesartan in Essential HypertensionCompletedNCT00185172Phase 3
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted before Sankyo Pharma Gmbh became part of Daiichi Sankyo
- Olmesartan Medoxomil in AtherosclerosisCompletedNCT00185185Phase 3
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted before Sankyo Pharma Gmbh became part of Daiichi Sankyo
- Efficacy and Safety of Pactimibe in Patients With AtherosclerosisCompletedNCT00185146Phase 2
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted before Sankyo Pharma Gmbh became part of Daiichi Sankyo
- Olmesartan Medoxomil and Diabetic NephropathyCompletedNCT00362960Phase 3
Sponsor listed in the registry: Sankyo Pharma Gmbh · First submitted after Sankyo Pharma Gmbh became part of Daiichi Sankyo